Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10500229 Targeted disruption of the MHC cell receptor

Patent 10500229 was granted and assigned to Sangamo Therapeutics on December, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

All edits

Edits on 9 Dec, 2023
"Add patent abstract"
Golden AI profile picture
Golden AI
edited on 9 Dec, 2023
Edits made to:
Article (+428 characters)
Article

Patent abstract

Disclosed herein are methods and compositions for inactivating MHC genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.

Edits on 31 May, 2023
"update inverses"
Golden AI profile picture
Golden AI
edited on 31 May, 2023
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
‌
US Patent 11661459 Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
0
Edits on 24 Apr, 2023
"update citations for inverse infoboxes"
Golden AI profile picture
Golden AI
edited on 24 Apr, 2023
Edits on 5 Apr, 2023
"Entity importer update"
Golden AI profile picture
Golden AI
edited on 5 Apr, 2023
Infobox
Is a
Patent
Patent
0
Patent Applicant
Sangamo Therapeutics
Sangamo Therapeutics
0
Current Assignee
Sangamo Therapeutics
Sangamo Therapeutics
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
105002290
Date of Patent
December 10, 2019
0
Patent Application Number
153807230
Date Filed
December 15, 2016
0
Patent Citations Received
‌
US Patent 11459372 Gene-edited natural killer cells
0
‌
US Patent 11591381 Gene-edited natural killer cells
0
Patent Primary Examiner
‌
Scott Long
0
Edits on 1 Mar, 2023
"update inverses"
Golden AI profile picture
Golden AI
edited on 1 Mar, 2023
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
‌
US Patent 11591381 Gene-edited natural killer cells
0
Edits on 8 Oct, 2022
"update inverses"
Golden AI profile picture
Golden AI
edited on 8 Oct, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
‌
US Patent 11459372 Gene-edited natural killer cells
0
Edits on 25 Sep, 2022
"Entity importer update"
Golden AI profile picture
Golden AI
edited on 25 Sep, 2022
Infobox
Is a
Patent
Patent
0
Patent Applicant
Sangamo Therapeutics
Sangamo Therapeutics
0
Current Assignee
Sangamo Therapeutics
Sangamo Therapeutics
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
105002290
Date of Patent
December 10, 2019
0
Patent Application Number
153807230
Date Filed
December 15, 2016
0
Patent Primary Examiner
‌
Scott Long
0
Edits on 31 Jan, 2022
"Created via: Entity Importer"
Golden AI profile picture
Golden AI
created this topic on 31 Jan, 2022
Edits made to:
Infobox (+9 properties)
‌

 US Patent 10500229 Targeted disruption of the MHC cell receptor

Infobox
Is a
Patent
Patent
Patent applicant
Sangamo Therapeutics
Sangamo Therapeutics
Current assignee
Sangamo Therapeutics
Sangamo Therapeutics
Patent jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent number
10500229
Date of patent
December 10, 2019
Patent application number
15380723
Date Filed
December 15, 2016
Patent primary examiner
‌
Scott Long

Find more entities like US Patent 10500229 Targeted disruption of the MHC cell receptor

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.